Early treatments to improve immune responses and control HIV-1
Official title: Early interventions at ART initiation to reduce the HIV-1 reservoir and enhance adaptive immune responses
Funded at University of Pennsylvania · NIH-11017367 · Data updated 2026-11-12
This study is looking at how giving a special antibody early in HIV treatment can help your body fight the virus better and reduce the amount of virus hiding in your system, with the hope of finding new ways to improve HIV care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 19, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $694,301 |
| NIH project number | 1R01AI184285-01A1 |
| Project ID | NIH-11017367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently been diagnosed with HIV-1 and are beginning antiviral therapy.
✕Less likely to help
Patients who are not newly diagnosed with HIV-1 or those who are not starting ART may not benefit from this research.
What this research studies
This research investigates how early interventions at the start of antiviral therapy (ART) can help control HIV-1 and reduce the viral reservoir in the body. By administering a specific broadly neutralizing antibody (bNAb) called 3BNC117, the study aims to enhance the immune response, particularly the activity of CD8+ T cells, which are crucial for fighting the virus. The research will analyze samples from a previous clinical trial to understand the mechanisms that lead to improved immune responses and potentially inform future treatments aimed at curing HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective strategies for controlling HIV-1 and improving long-term health outcomes for patients living with the virus.
How similar studies have gone: Previous studies, such as the eCLEAR trial, have shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Betts, Michael R — University of Pennsylvania
- Study coordinator: Betts, Michael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.